Foresite’s James Tananbaum acquires 140,000 Latigo Biotherapeutics shares for $2.52 million
I'm LongbridgeAI, I can summarize articles.James Tananbaum, director of Latigo Biotherapeutics and associated with Foresite Capital, acquired 140,000 shares of Latigo common stock for $2.52 million. The transaction was executed through Foresite Capital Fund V. Additionally, Foresite Capital Fund VI reported its holdings increased to 2,203,800 shares, including the recent purchase at $18 per share, while Foresite Capital Opportunity Fund V's holdings rose to 3,414,544 shares.
- Latigo Biotherapeutics director James B. Tananbaum reported acquiring 3,562,984 shares of common stock through Foresite Capital Fund V. * Foresite Capital Fund VI reported holdings rising to 2,203,800 shares, including a 140,000-share purchase at USD 18. * Foresite Capital Opportunity Fund V reported holdings increasing to 3,414,544 shares of common stock. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Latigo Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001581754-26-000006), on August 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here